On the sidelines of the World Economic Forum, DNDi and the Hepatitis Fund (End Hep 2030) are hosting an event at the Davos SDG Tent on the elimination of viral hepatitis.
The World Health Assembly calls for elimination of viral hepatitis as a public health threat by 2030 and yet most countries are not on track. No major philanthropic funders have committed to this global goal despite the 1.5 million deaths which could be averted and a strong cost-benefit argument.
Existing investments from global partners have proven to catalyze development and scale up of national programmes. However, innovative financing and blended finance mechanisms have been vastly underutilized especially when compared to their use for other major disease areas (e.g., malaria, TB, NCDs). The opportunity for blended finance – i.e., strategic use of development finance for the mobilization of additional finance towards hepatitis elimination – is particularly strong for hepatitis C, which has an effective cure.
A key question remains: How to attract capital – public and private – toward projects that contribute to viral hepatitis elimination while ensuring sustainable impact as part of national universal health coverage plans?
Date: Wednesday, 25 May 2022
Venue: Ocean Room
- Helen Clarke, Former Prime Minister of New Zealand, Board chair of the Partnership for Maternal, Newborn & Child Health (PMNCH)
- Dr Rania Al-Mashat, Minister of International Cooperation, Arab Republic of Egypt
- Dr Tenu Avafia, Deputy Executive Director, Unitaid
- Charles Gore, Executive Director, Medicines Patent Pool
- Dr Sherine Helmy, CEO, Pharco Pharmaceuticals
- Dr Mariam Jashi, Board Member, UNITE Network and former Parliamentarian of Georgia
- Finn Jarle Rode, Executive Director, The Hepatitis Fund
- Dr Bernard Pécoul, Executive Director, DNDi
- Dr Su Wang, Former President, World Hepatitis Alliance
- Dr John Ward, Director, Task Force for Global Health